Is the business good?
How good a business is AGIO?
Agios Pharmaceuticals, Inc. keeps −720% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−720%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- +2.3%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 527%
R&D as % of revenue
- Gross margin
- 90%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −165% |
| FY2022 | −2732% |
| FY2023 | −1460% |
| FY2024 | −1166% |
| FY2025 | −874% |
Details›
- Gross margin12 months to Q1 2026
- 90%
- Operating margin12 months to Q1 2026
- −720%
- Net margin12 months to Q1 2026
- −640%
- Free cash flow margin
- −583%
- R&D as % of revenue
- 527%
- Revenue, trailing twelve months
- $66M
- Free cash flow, trailing twelve months
- −$385M
- Net income, trailing twelve months
- −$423M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.